HRP20141230T1 - Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells - Google Patents

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells Download PDF

Info

Publication number
HRP20141230T1
HRP20141230T1 HRP20141230AT HRP20141230T HRP20141230T1 HR P20141230 T1 HRP20141230 T1 HR P20141230T1 HR P20141230A T HRP20141230A T HR P20141230AT HR P20141230 T HRP20141230 T HR P20141230T HR P20141230 T1 HRP20141230 T1 HR P20141230T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
tumor cells
preparation according
dendritic cells
hydrostatic pressure
Prior art date
Application number
HRP20141230AT
Other languages
Croatian (hr)
Inventor
Jirina Bartunková
Radek Spísek
Original Assignee
SOTIO a.s.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11172622A external-priority patent/EP2543386A1/en
Application filed by SOTIO a.s. filed Critical SOTIO a.s.
Publication of HRP20141230T1 publication Critical patent/HRP20141230T1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (14)

1. Farmaceutski pripravak namijenjen poticanju imunosnog odgovora na tumorske stanice, naznačen time što sadrži a) tumorske stanice koje postaju apoptotske zbog obrade visokim hidrostatskim tlakom jednakim ili većim od 100 MPa u trajanju od 10 minuta do 2 sata i b) dendritičke stanice.1. Pharmaceutical preparation intended to stimulate the immune response to tumor cells, indicated by the fact that it contains a) tumor cells that become apoptotic due to treatment with high hydrostatic pressure equal to or greater than 100 MPa for a duration of 10 minutes to 2 hours and b) dendritic cells. 2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se tumorske stanice obrađuje hidrostatskim tlakom najmanje 10 minuta pod tlakom od najmanje 200 MPa.2. Pharmaceutical preparation according to patent claim 1, characterized in that the tumor cells are treated with hydrostatic pressure for at least 10 minutes under a pressure of at least 200 MPa. 3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se tumorske stanice obrađuje hidrostatskim tlakom od 200-300 MPa.3. Pharmaceutical preparation according to claim 1, characterized in that the tumor cells are treated with a hydrostatic pressure of 200-300 MPa. 4. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što apoptotske tumorske stanice nisu nekrotične.4. Pharmaceutical preparation according to any one of claims 1-3, characterized in that the apoptotic tumor cells are not necrotic. 5. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se tumorske stanice dobiva iz tumorskih staničnih linija.5. Pharmaceutical preparation according to any of the previous patent claims, characterized in that the tumor cells are obtained from tumor cell lines. 6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što se tumorske stanice dobiva iz tumora izoliranog iz pacijenta kojeg treba liječiti.6. A pharmaceutical preparation according to any one of claims 1-4, characterized in that the tumor cells are obtained from a tumor isolated from a patient to be treated. 7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što su nezrele dendritičke stanice opterećene s apoptotskim tumorskim stanicama obrađenim visokim hidrostatskim tlakom.7. Pharmaceutical preparation according to any one of patent claims 1-6, characterized in that immature dendritic cells are loaded with apoptotic tumor cells treated with high hydrostatic pressure. 8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što se nezrele dendritičke stanice dobivaju leukoferezom.8. Pharmaceutical preparation according to patent claim 7, characterized in that immature dendritic cells are obtained by leukopheresis. 9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što se nezrele dendritičke stanice dobivaju leukoferezom i uzgojem in vitro u prisutnosti citokina.9. Pharmaceutical preparation according to patent claim 8, characterized in that immature dendritic cells are obtained by leukopheresis and cultivation in vitro in the presence of cytokines. 10. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi kod pacijenata oboljelih od ranog kao i kasnog stadija raka.10. Pharmaceutical preparation according to any one of patent claims 1 to 9, characterized in that it is intended for use in patients suffering from early as well as late stage cancer. 11. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju raka, kojeg čine rak prostate, rak jajnika ili akutna limfoblastična leukemija.11. Pharmaceutical preparation according to any one of patent claims 1 to 9, characterized in that it is intended for use in the treatment of cancer, which consists of prostate cancer, ovarian cancer or acute lymphoblastic leukemia. 12. Postupak priprave farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što se nezrele dendritičke stanice stavlja u kontakt s apoptotskim tumorskim stanicama obrađenim visokim hidrostatskim tlakom jednakim ili većim od 100 MPa i naknadno zrenje dendritičkih stanica.12. Process for the preparation of a pharmaceutical preparation according to any one of patent claims 1-9, characterized in that immature dendritic cells are brought into contact with apoptotic tumor cells treated with high hydrostatic pressure equal to or greater than 100 MPa and subsequent maturation of dendritic cells. 13. Postupak priprave farmaceutskog pripravka u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u cijepljenju od ljudskog raka koje se sastoji u stavljanju u kontakt nezrelih dendritičkih stanica s tumorskim stanicama, gdje se navedene tumorske stanice prevodi u apoptotski stadij obradom u trajanju od 10 minuta do 2 sata visokim hidrostatskim tlakom jednakim ili većim od 100 MPa, gdje su dendritičke stanice izborno zrele prije primjene farmaceutskog pripravka.13. The method of preparing a pharmaceutical preparation in accordance with patent claim 12, characterized in that it is intended for use in vaccination against human cancer, which consists in bringing immature dendritic cells into contact with tumor cells, where said tumor cells are translated into the apoptotic stage by processing for a duration of from 10 minutes to 2 hours with high hydrostatic pressure equal to or greater than 100 MPa, where the dendritic cells are optionally matured before the administration of the pharmaceutical preparation. 14. Postupak priprave farmaceutskog pripravka u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u cijepljenju od ljudskog raka koje se sastoji u stavljanju u kontakt nezrelih dendritičkih stanica s tumorskim stanicama dobivenim iz tumorske stanične linije, prevedenim u apoptotski stadij obradom u trajanju od 10 minuta do 2 sata visokim hidrostatskim tlakom jednakim ili većim od 100 MPa, gdje su dendritičke stanice izborno zrele prije primjene farmaceutskog pripravka.14. The method of preparing a pharmaceutical preparation in accordance with patent claim 12, characterized in that it is intended for use in vaccination against human cancer, which consists in bringing immature dendritic cells into contact with tumor cells obtained from a tumor cell line, converted to the apoptotic stage by processing for a duration of from 10 minutes to 2 hours with high hydrostatic pressure equal to or greater than 100 MPa, where the dendritic cells are optionally matured before the administration of the pharmaceutical preparation.
HRP20141230AT 2011-07-05 2014-12-17 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells HRP20141230T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
PCT/EP2012/062950 WO2013004708A1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
EP12734884.5A EP2691110B1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (1)

Publication Number Publication Date
HRP20141230T1 true HRP20141230T1 (en) 2015-02-13

Family

ID=50023029

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141230AT HRP20141230T1 (en) 2011-07-05 2014-12-17 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Country Status (7)

Country Link
JP (1) JP6235085B2 (en)
CL (1) CL2013003282A1 (en)
CY (1) CY1115803T1 (en)
HR (1) HRP20141230T1 (en)
IL (2) IL229702A (en)
MX (1) MX2013013243A (en)
ZA (1) ZA201307886B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852672C (en) 2011-10-17 2021-07-20 Massachusetts Institute Of Technology A microfluidic system and method for delivering a payload into a cell by causing perturbations in a cell membrane of the cell
JP6502940B2 (en) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー Selective delivery of substances to cells
KR20170074235A (en) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 Delivery of biomolecules to immune cells
CN113897285A (en) 2014-11-14 2022-01-07 麻省理工学院 Disruption and field-effected delivery of compounds and compositions into cells
CN107250373A (en) 2015-01-12 2017-10-13 麻省理工学院 The gene editing realized is delivered by microfluid
EP4257675A3 (en) 2015-07-09 2024-01-03 Massachusetts Institute of Technology Delivery of materials to anucleate cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases

Also Published As

Publication number Publication date
IL229702A0 (en) 2014-01-30
IL229702A (en) 2016-09-29
JP2017025066A (en) 2017-02-02
IL247781A0 (en) 2016-11-30
CY1115803T1 (en) 2017-01-25
CL2013003282A1 (en) 2014-10-10
JP6235085B2 (en) 2017-11-22
ZA201307886B (en) 2015-03-25
IL247781B (en) 2019-11-28
MX2013013243A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
HRP20141230T1 (en) Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells
RU2012127685A (en) DEVICES AND METHODS FOR ACTIVE CELLULAR CANCER IMMUNOTHERAPY BY APPLICATION OF TUMOR CELLS DESTROYED BY HIGH HYDROSTATIC PRESSURE AND DENDRITIC CELLS
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
MX2019008419A (en) Methods of manufacture of nut flours and formulations for oral immunotherapy.
JP2010516259A5 (en)
WO2013130102A3 (en) Dual ox40 agonist/il-2 cancer therapy methods
WO2015035250A3 (en) Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
MX345704B (en) Bovine vaccines and methods.
JP2013530155A5 (en)
WO2014183033A3 (en) G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal
MX2019003134A (en) Combination therapy.
MX2020006944A (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
SI2941257T1 (en) Disease therapy using a tolerogenic pharmaceutical preparation
JP2018522880A5 (en)
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2022003039A (en) Universal donor selection method to identify nk-cell-donors.
WO2013096732A3 (en) Methods of treating or preventing viral diseases by blocking interleukin-21
EA201591623A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASES BY INHIBITING TRF-β ACTIVITY
GB201104897D0 (en) Method for the production of protein complexes and vaccine compositions comprising the same